TG Therapeutics advancing CAR T-cell therapy toward trial in MS

Multiple Sclerosis News Today

Factuality

Ownership

TG Therapeutics advancing CAR T-cell therapy toward trial in MS

In a new deal, TG Therapeutics will use MaxCyte’s engineering technology to develop and manufacture its off-the-shelf CAR T-cell therapy candidate azercabtagene zapreleucel — azer-cel for short — for adults with progressive forms of multiple sclerosis (MS). The experimental treatment is being advanced toward a Phase 1 clinical trial expected to enroll more than 30 […] The post TG Therapeutics advancing CAR T-cell therapy toward Phase 1 trial app…